Thirteen countries collaborate on Africa's largest Covid-19 treatment trial.

Led by DNDi, the ANTICOV trial aims to explore treatments that can be used to prevent hospitalizations the continent cannot afford.

An international network of research institutions has joined forces with thirteen African countries to launch the largest Covid-19 clinical trial in mild-to-moderate outpatients across Africa. Called the ANTICOV trial, the study which will involve 19 sites across the 13 countries involved, is looking to test the safety and efficacy of treatments in 2,000 to 3,000 mild-to-moderate Covid-19 patients. The trial is looking to explore whether patients infected by the virus can be treated earlier to avoid hospitalizations given the limited availability of intensive care units across the continent.

Countries included in the trial include Burkina Faso, Cameroon, Côte d’Ivoire, the Democratic Republic of Congo (DRC), Equatorial Guinea, Ethiopia, Ghana, Guinea, Kenya, Mali, Mozambique, Sudan, and Uganda. The open-labelled, randomized, comparative and ‘adaptive platform trial’ has been hailed for bringing together such a large number of African countries to help get answers for the African context. Coordinated by the Drugs for Neglected Diseases initiative (DNDi), the ANTICOV consortium is made up of 26 prominent African and global organizations including Kenya Medical Research Institute (KEMRI) and Tanzania’s Ifakara Health Institute.